-
Libya's pay strike rallies teachers across divided nation
-
German sugar tax sparks new government row
-
Four-member crew blasts off for International Space Station
-
Musk returns to US government for Pentagon war study
-
i-payout Expands True Local Payment Capabilities to Help Enterprises Pay Recipients Globally
-
Stocks slide as bond yields spike
-
Botched US execution prompts global calls to scrap death penalty
-
Thousands rally as EU chief urges respect for Kosovo war crimes court
-
Algeria adopts law imposing death penalty on forest arsonists
-
Man City sponsor Etihad says considering legal action against Premier League
-
France unveils cost-cutting 2027 budget as borrowing costs rise
-
Family of woman killed by US immigration agent sues Trump administration
-
Brazil court orders removal of fake posts amid patron saint election row
-
French school protests spread as fires, blockades deepen unrest
-
Italy's firefighting planes return home after scorching summer
-
UK tribunal overturns ban on Naomi Campbell leading charities
-
How airlines try to make sure pilots are safe to fly
-
Louvre launches appeal as part of new fundraising drive
-
Bolivia's attorney general arrested for alleged money laundering and drug trafficking
-
Croatian ex-international Simic charged in graft case
-
Zverev beats Norrie to kick off Sinner-less China Open
-
76% of Treasury Teams Hit by Fraud as Deepfake Attacks Rise, Treasury Dragons & nsKnox 2026 Index Finds
-
Wall Street stocks rise after bond yield spike eases
-
Malawi ex-army chief arrested following allegations over Sudan arms
-
Finland investigates suspected break-ins at MPs homes
-
German fuel price cuts kick in to ease Mideast energy shock
-
London's Bayeux Tapestry show to offer audio tour for blind people
-
'It's history': Zverev against shortening Grand Slam match format
-
Smouldering bins, halted trams as French pupils protest
-
From Question to Action: Leverate Launches ASK, Its Native AI Assistant for Traders
-
Malone Life and Pensions Expands Internationally Beyond the European Union
-
UN says strikes on Afghanistan kill 10 civilians
-
England paceman Archer rested for ODI tri-series
-
Two Russian drones hit major bridge in Kyiv
-
Queiroz exits Ghana as Black Stars crisis deepens
-
Alcaraz begins Japan Open defence with win over Michelsen
-
ALEX BODI VE ALMAN ŞİRKETLER GRUBUNDAN HALLE’DE 166 DAİREYE YATIRIM
-
ALEX BODI DAN KONGLOMERAT JERMAN BERINVESTASI PADA 166 UNIT HUNIAN DI HALLE
-
อเล็กซ์ โบดี และกลุ่มบริษัทจากเยอรมนีลงทุนในอพาร์ตเมนต์ 166 ยูนิตที่เมืองฮัลเลอ
-
Ronaldo's Portugal future in doubt after walkout
-
ALEX BODI A NĚMECKÝ KONCERN INVESTUJÍ DO 166 BYTŮ V HALLE
-
European stocks drop as debt fears send bond yields soaring
-
ALEX BODI OCH TYSK KONCERN INVESTERAR I 166 LÄGENHETER I HALLE
-
Ο ΑΛΕΞ ΜΠΟΝΤΙ ΚΑΙ ΓΕΡΜΑΝΙΚΟΣ ΟΜΙΛΟΣ ΕΠΕΝΔΥΟΥΝ ΣΕ 166 ΔΙΑΜΕΡΙΣΜΑΤΑ ΣΤΟ ΧΑΛΕ
-
England forward Toney pleads not guilty to nightclub assault
-
India to clash with Pakistan as Eala suffers Games heartbreak
-
Tom Kim finishes marathon Asian Games second round under floodlights
-
Judoka wins Asian Games gold after honouring dying grandmother's wish
-
Work on migrant return hubs progressing well, EU countries say
-
Kenyan island paradise fears damage from mega-refinery
Decade since Ebola, Sierra Leone fights another deadly fever
Rummaging in the darkness of a tiny mud and thatch home in eastern Sierra Leone, ecologist James Koninga plucks a metal rat trap from under a collapsed bedframe.
The 62-year-old belongs to a group of researchers tracking the deadly Lassa fever, a viral haemorrhagic illness endemic in several West African countries and transmitted by infected rats.
Koninga knows all too well what is at stake -- he spent a gruelling 20 days in hospital with a Lassa-induced fever, headache and diarrhoea as a young researcher 30 years ago.
"I thought I was going away, I was going to die," he said.
Ten years ago, the haemorrhagic Ebola virus devastated this region, killing over 11,000 people across Guinea, Sierra Leone and Liberia.
Sierra Leone has not recorded an Ebola case since the outbreak ended in 2016, thanks partly to a vaccine rollout.
In Kenema district, an early Ebola epicentre, scientists are using the lessons learned a decade ago to try to stop Lassa fever in its tracks.
With an overall fatality rate of one percent, Lassa is nowhere near as deadly as Ebola, which kills on average 50 percent of sufferers, according to the World Health Organization.
But one in five Lassa infections can result in severe illness with a fatality rate of 15 percent.
While cases have largely plateaued in Sierra Leone, researchers are seeing a spread beyond traditional Lassa hotspots.
There is no licensed vaccine and only limited treatment, with the scars of Ebola preventing many from seeking early life-saving help.
- Living with rats -
Monitoring the rodent population is crucial in remote villages like Mapuma, where some 20 houses lie enveloped by dense forest.
"Rats burrow inside the houses for shelter," explained Koninga, donning a face shield and gloves.
Humans usually contract Lassa virus after having contact with the urine, saliva or droppings of infected rats.
"If people come in from the bush with cuts on them and lie on the bed, they could be infected."
Proximity to the forest, rudimentary mud construction, and uncovered grain and water storage make the dwellings "five-star hotels" for rats, said Lansana Kanneh, 58, field supervisor at the region's Kenema Government Hospital (KGH).
"Food is scarce for these people so sometimes they even eat the food that has been partially eaten by the rodent," he added.
Trappers can find up to 20 rats per day in some villages.
After identifying if the rodents are the Lassa-carrying Mastomys variety, samples are collected for analysis.
The rats then receive an injection that prevents viral transmission before being released.
Lassa virus infects between 100,000 and 300,000 people annually in West Africa, killing roughly 5,000, according to the Africa Centres for Disease Control and Prevention.
But the figures likely underestimate the true scale given surveillance challenges.
Admissions to the Lassa unit at KGH -- Sierra Leone's only dedicated treatment centre -– have declined in the past decade.
Patients normally arrive in the 14-bed isolation ward during the dry season from November to May, but this once-predictable pattern is increasingly uncertain.
- 'Lassa blood' -
"Now we see cases year-round," said Donald Grant, head of the KGH Lassa fever programme.
The team are also noticing Lassa beyond traditionally endemic zones, with Grant suspecting an improvement in testing as well as deforestation driving rodents into closer contact with humans.
Over the past decade, KGH has also seen an alarming uptick in Lassa patient mortality, which now stands at over 50 percent.
"We've seen a lot of these cases coming in in their late stages," said Kanneh.
"Sometimes they only spend 24 to 48 hours in the hospital, and they die."
Rapid detection is the key to survival, but non-specific febrile symptoms mean Lassa is commonly misdiagnosed as malaria, cholera or typhoid.
Hours-long journeys on dirt roads prevent many from seeking treatment.
As does the trauma from Ebola, which killed some 4,000 Sierra Leoneans.
"The community people thought that Ebola was brought by the health workers," Kanneh said, explaining that a lingering mistrust contributed to reduced admissions.
A KGH team raises awareness in local communities about seeking rapid help and ensuring good domestic hygiene.
It is a message well-received by Musa Mosoh, a 53-year-old Lassa survivor who lost seven family members to the illness.
As the morning rain fell in his village of Panguma -- a Lassa red zone -- Mosoh recalled how his family had faced stigma from the community.
"Now... people have got the understanding we are not from Lassa blood, it's just a sickness."
Mosoh tells those with a continuous fever or headache to go straight to the hospital, and even keeps cats to repel any virus-carrying rodents.
Grant, the doctor, is hopeful of a vaccine in the next few years.
Participants in Nigeria and Liberia are currently being given the first-ever Lassa vaccine to reach phase two trials -- the midway point of testing in humans.
But Grant still urges caution.
Ebola "taught us a lesson that we need not wait until that critical moment that it overwhelms all of us," he said.
"We need to act now."
F.Wagner--VB